TTrialPathMatch Me to Trials
← Back to trials
RecruitingLung Cancer, Nonsmall Cell

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Sponsor: Abramson Cancer Center at Penn Medicine

You may qualify if…

  • ✓ Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • ✓ Prior exposure to at least 1 line of therapy
  • ✓ Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
  • ✓ ECOG PS 0-2

You may not qualify if…

  • ✕ Presence of a driver mutation that is susceptible to targeted therapy
  • ✕ No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
  • ✕ Other active invasive malignancy requiring ongoing therapy
  • ✕ Evidence of progressing or untreated brain metastases
  • ✕ Evidence or history of leptomeningeal disease
  • ✕ Uncontrolled tumor related pain
  • ✕ History of an autoimmune disease or IPF

Where it's recruiting

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT04691817 · last updated 2026-01-07